No Detail Found!

Correlation of serum uromodulin levels with renal fibrosis and renal function progression in patients with CKD

Author(s)
Chen Jie Department of Nephrology, Ningbo Yinzhou No. 2 Hospital,Ningbo, Zhejiang Province,China
Ying Yi-Ying Department of Nephrology, Ningbo Yinzhou No. 2 Hospital,Ningbo, Zhejiang Province,China
Chen Miao Department of Nephrology, Ningbo Yinzhou No. 2 Hospital,Ningbo, Zhejiang Province,China
Abstract
To explore the relationship of serum uromodulin levels with renal function progression and renal fibrosis in chronic kidney disease (CKD) patients. Totally 168 CKD patients treated in Department of Nephrology of the present hospital between June 2017 and June 2019 were recruited. These patients were allocated to the deterioration and control groups according to the estimated glomerular filtration rate (eGFR). Multi-factor Logistic regression analysis was utilized for the correlation factors influencing renal function progression and the correlation between serum uromodulin and renal fibrosis was also compared. Number of patients receiving ARB or ACEI drugs intervention was lower in the deterioration group than that in the control group (P<0.05). 24-hour urine protein quantification and HA were higher, while eGFR and uromodulin were lower in the deterioration group compared with the control group (both P<0.05). eGFR (OR=0.373) and uromodulin (OR=0.717) were the protective factors for renal function progression. The risk of renal fibrosis was higher in the deterioration group compared with the control group (P<0.05). Uromodulin was significantly higher in the fibrosis group compared with the normal group (P<0.05). Serum uromodulin is an independent risk factor for renal function progression, and is remarkably correlated with renal fibrosis, which deserves clinical promotion.
Publication Details
Page(s) 2417-2422
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: S6, Year: 2021

Request the full text from PASTIC

Keywords
Chronic Kidney Disease, serum uromodulin, Estimated Glomerular filtration rate, renal fibrosis
References
Bajaj A,Xie D,Cedillo-Couvert E,Charleston J,Chen J,Deo R,Feldman HI,Go AS,He J,Horwitz E,Kallem R,Rahman M,Weir MR,Anderson AH,Rader DJ .2019 .Lipids, apolipoproteins and risk of atherosclerotic cardiovascular disease in persons with CKD. Am. J. Kidney Dis, 73(6) : 827-836.
Bostom A,Steubl D,Garimella PS,Franceschini N,Roberts MB,Pasch A,Ix JH,Tuttle KR,Ivanova A,Shireman T,Kim SJ,Gohh R,Weiner DE,Levey AS,Hsu CY,Kusek JW,Eaton CB .2018 .Serum uromodulin: a biomarker of long-term kidney allograft failure. Am. J. Nephrol., 47(4) : 275-282.
Chang CC,Chen CY,Huang CH,Wu CL,Wu HM,Chiu PF,Kor CT,Chen TH,Chang GD,Kuo CC,Wen HC,Huang CY,Chang CH .2017 .Urinary glycated uromodulin in diabetic kidney disease. Clin. Sci, 131(15) : 1815-1829.
Nephrologist Chinese,Association Chinese .2019 .The application of vitamin D and its analogues in patients with chronic kidney disease: The Chinese practice program (. Zhonghua Neike Zazhi, 59(02) : 104-116.
Delgado GE,Kleber ME,Scharnagl H,Kramer BK,März W,Scherberich JE .2017 .Serum uromodulin and mortality risk in patients undergoing coronary angiography. J. Am. Soc. Nephrol., 28(7) : 2201-2210.
Devuyst O,Olinger E,Rampoldi L E .2017 .Uromodulin: From physiology to rare and complex kidney disorders. Nat. Rev. Nephrol., 13(9) : 525-544.
Ferro CJ,Mark PB,Kanbay M,Sarafidis P,Heine GH,Rossignol P,Massy ZA,Mallamaci F,Valdivielso JM,Malyszko J,Verhaar MC,Ekart R,Vanholder R,London G,Ortiz A,Zoccali C .2018 .Lipid management in patients with chronic kidney disease. Nat. Rev. Nephrol., 14(12) : 727-749.
Garimella PS,Bartz TM,Ix JH,Chonchol M,Shlipak MG,Devarajan P,Bennett MR,Sarnak MJ MR .2017 .Urinary uromodulin and risk of urinary tract infections: The cardiovascular health study. Am. J. Kidney Dis, 69(6) : 744-751.
Garimella PS,Sarnak MJ PS .2017 .Uromodulin in kidney health and disease. Curr. Opin. Nephrol, 26(2) : 136-142.
Disease: Improving Global Outcomes (KDIGO). Kidney .2013 .KDIGO 2012 clinical practice guideline for evaluation and management of chronic kidney disease. Kidney Int. Suppl., 3(1) : 1-150.
Ku E,Yang W,McCulloch CE,Feldman HI,Go AS,Lash J,Bansal N,He J,Horwitz E,Ricardo AC,Shafi T,Sondheimer J,Townsend RR,Waikar SS,Hsu CY,CRIC Study Investigators CY .2020 .Race and mortality in CKD and dialysis: Findings from the chronic renal insufficiency cohort (CRIC) study. Am. J. Kidney Dis, 75(3) : 394-403.
Lamprea-Montealegre JA,Staplin N,Herrington WG,Haynes R,Emberson J,Baigent C,de Boer IH .2020 .Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clin. J. Am. Soc. Nephrol., 15(1) : 47-60.
Leiherer A,Muendlein A,Saely CH,Brandtner EM,Geiger K,Fraunberger P,Drexel H P .2018 .The value of uromodulin as a new serum marker to predict decline in renal function. J. Hypertens., 36(1) : 110-118.
Lew QLJ,Allen JC,Nguyen F,Tan NC,Jafar TH .2018 .Factors associated with chronic kidney disease and their clinical utility in primary care clinics in a multi-ethnic Southeast Asian population. Nephron, 138(3) : 202-213.
Tokonami N,Olinger E,Debaix H,Houillier P,Devuyst O .2018 .The excretion of uromodulin is modulated by the calcium-sensing receptor. Kidney Int, 94(5) : 882-886.
Tokonami N,Takata T,Beyeler J,Ehrbar I,Yoshifuji A,Christensen EI,Loffing J,Devuyst O,Olinger EG .2018 .Uromodulin is expressed in the distal convoluted tubule, where it is critical for regulation of the sodium chloride cotransporter NCC. , 94(4) : 701-715.
Wang M,Zhang X,Sui Z,Bai L,Wang Y,Zuo L,Wang M .2020 .Impact of arterial stiffness on prognosis in non-diabetic pre-dialysis patients with stages 3-5 chronic kidney disease. Zhonghua Linchuang Yishi Zazhi (Electronic Edition), 14(03) : 170-174.
0

Citations

0

Downloads

11

Views